A Phase II, Open-Label, Single-Arm Study to Assess the Efficacy and Safety of Decapeptyl SR (3 mg and 11.25 mg formulations) when administered by subcutaneous injection.
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2016
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms DISC
- 07 Jun 2017 Biomarkers information updated
- 24 Jul 2012 Status changed from active, no longer recruiting to completed as reported by UKCRN.
- 31 May 2012 Location (England) added as reported by United Kingdom Clinical Research Network record.